CMR Prognostic Markers in Ischemic Heart Disease

ConditionsIschemic Heart Disease (IHD)Myocardial Infarction (MI)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorChinese Academy of Medical Sciences, Fuwai Hospital

About this trial

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury.

Cardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences.

This multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values.

Long-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (≥18 years of age).

Patients with ischemic heart disease, including prior or recent myocardial infarction, who underwent clinically indicated cardiac magnetic resonance (CMR) imaging.

Availability of analyzable CMR images, including but not limited to cine imaging, late gadolinium enhancement (LGE), and parametric mapping sequences (T1 and/or T2 mapping), as applicable.

Availability of baseline clinical data and longitudinal follow-up information.

Disqualifiers

Poor image quality or incomplete CMR data precluding quantitative analysis.

Presence of other severe comorbid conditions expected to significantly affect survival or clinical outcomes.

Missing key clinical outcome data during follow-up.

Trial population

This observational study includes adult patients with ischemic heart disease who underwent clinically indicated cardiac magnetic resonance imaging as part of routine clinical care at participating centers. The study population represents a real-world cohort with a broad spectrum of ischemic heart disease, including myocardial infarction, and is characterized by comprehensive CMR imaging data, detailed clinical information, and long-term follow-up for cardiovascular outcomes.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Cardiac Magnetic Resonance Imaging
Diagnostic test
Cardiac magnetic resonance imaging performed as part of routine clinical care. Imaging data are used for observational research analyses only, without altering clinical management.

Treatment groups

1,000 Participants

are divided into 1 treatment group

Group A: Ischemic Heart Disease Cohort1 intervention

Trial outcomes

Primary outcomes

Major Adverse Cardiovascular and Cerebrovascular Events

Major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, and unplanned coronary revascularization. Events are identified through longitudinal clinical follow-up and review of medical records.

Time frame

From the date of index clinically indicated cardiac magnetic resonance imaging to the date of first occurrence of a MACCE event, death, or last available clinical follow-up, whichever came first, assessed up to 10 years.

Secondary outcomes

Cardiovascular Death

Death resulting from cardiovascular causes, including myocardial infarction, heart failure, fatal arrhythmia, or sudden cardiac death, as determined by clinical records and follow-up data.

Time frame

From the date of index clinically indicated cardiac magnetic resonance imaging to the date of cardiovascular death or last available clinical follow-up, whichever came first, assessed up to 10 years.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese Academy of Medical Sciences, Fuwai Hospital

Lead sponsor

National Natural Science Foundation of China

Collaborator

Beijing Natural Science Foundation